Pieces

Proprietary generative AI is the product. The Pieces Intelligence Platform condenses and summarises clinical data and pre generates documentation directly inside the EHR, the company is physician led and NIH backed, and it reports more than 10 million AI generated clinical documents produced. Nothing here is a workflow layer over someone else's model, and the company built its own hallucination classification research rather than buying one.

The described oversight architecture is genuinely more developed than most of this category, and it deserves saying plainly given the enforcement history. Pieces described a closed loop: random clinical summaries are selected for review, an adversarial AI model flags any that may contain a severe hallucination using evidence drawn from the medical record, flagged summaries are referred to a physician who reviews and assesses them, corrects any severe hallucination found, and comments on the changes made. That is sampling, automated detection, a human adjudicator and a feedback path, which is more machinery than any other vendor in this lane has described. Held at B for two reasons. The rate that loop produces is the exact figure a state regulator challenged, so the mechanism is described while its output is disputed. And no sampling fraction, no severity threshold, no adjudication methodology and no inter rater agreement is published, so a buyer cannot judge whether the loop would catch what it needs to catch.

The most instructive transparency case in this category, and the grade needs its context. Pieces did something almost nobody in this lane does: it built a risk classification system for generative AI hallucinations over several years and published quantified error figures, advertising a critical hallucination rate and a severe hallucination rate of under 0.001 percent and under 1 per 100,000. Those specific figures then became the subject of a Texas Attorney General action alleging the supporting metrics were inaccurate, and the central remedy in the resulting agreement is clear and conspicuous disclosure of how such metrics are calculated. Pieces denies the metrics were inaccurate. Graded C because a published number whose derivation is contested and undisclosed does not let a buyer evaluate the product: it is not clear what population was sampled, how severity was defined, or who adjudicated. No base model is named, and no updated methodology has been published since the acquisition. The lesson generalises and is not to the company's discredit: it published a rate, which invited scrutiny, and almost no competitor publishes one to be scrutinised.

Deployment scale substituting for evidence of benefit, which this index consistently grades C. More than 10 million AI generated clinical documents and use across hospitals and health systems nationally, plus NIH funding as research backing. Deployment at four major Texas hospitals is unusually well corroborated, though by an odd route: it is established by a state attorney general's investigation rather than by a case study. No peer reviewed outcome study, no controlled evaluation and no independently validated accuracy figure was located, and the accuracy metrics that did exist are contested. IMPORTANT ATTRIBUTION CAUTION: the strong figures published alongside SmarterNotes, including 12 million cases analysed, 36 percent of encounters with new comorbidity opportunities, a 5 to 1 return from day one and about 2.5 million dollars in annual net new revenue per 10,000 discharges, are attributed by the vendor to the SmarterDx offering rather than to the Pieces summariser. They are not evidence about this product.

No retention statement, no training use statement, no de identification posture and no PHI handling detail was located on any retrieved surface, and the Pieces site no longer exists independently to carry one. Not Rated records that the evidence was not retrieved. Two facts a buyer should carry into the diligence conversation. The Texas action established that at least four major Texas hospitals were sending patient data to Pieces in real time, so the PHI flow is continuous rather than batch. And the company has since been acquired, so the estate holding that data now sits inside a private equity backed revenue cycle platform assembled from four businesses. Ask where the data went, who holds it now, and what the BAA chain looks like after the transaction.

No HIPAA compliance statement and no business associate agreement terms were located. The acquiring group publishes corporate terms of service and a privacy policy but nothing specific to this product's PHI handling was retrieved. Establish which contracting entity now holds the BAA following the September 2025 acquisition, since the counterparty a health system originally signed with no longer exists as an independent company.

No SOC 2, ISO 27001, HITRUST or other attestation was located, and no trust centre or security page specific to this product was found. Not Rated reflects absent retrieval rather than an assessed weakness.

An unusual entry on this axis and the distinction matters. No FDA clearance, device authorisation or clinical decision support exemption analysis was located for a product that summarises a patient's condition and treatment for clinical staff. What does exist is a regulatory instrument of an entirely different kind: a five year Assurance of Voluntary Compliance entered with the Texas Attorney General on 18 September 2024 under the Texas Deceptive Trade Practices Consumer Protection Act, carrying obligations on marketing disclosures, prohibitions on misrepresentation including as to the independence of endorsers and reviewers, and a requirement to respond to the Attorney General's information requests within 30 days. Read it for what it is. It is a consumer protection instrument governing how the product may be described, not a device authorisation, not a safety assessment and not a finding that the product caused harm. It is graded here rather than ignored because it is a live regulatory obligation a buyer should know about, and because it is the only formal regulatory engagement this category has yet produced.

The grade describes disclosure and incentive structure, not wrongdoing, and the facts should be read carefully in both directions. On 18 September 2024 the Texas Attorney General announced the first state enforcement settlement in the United States involving a healthcare generative AI product, alleging that Pieces made false, misleading or deceptive claims about the accuracy of products used by at least four major Texas hospitals to summarise patient conditions and treatment. The matter resolved by Assurance of Voluntary Compliance. There was NO monetary penalty, NO admission of liability and NO adjudicated finding of wrongdoing. Pieces publicly denied wrongdoing, disputed that it had misrepresented its hallucination rate, and stated that the Attorney General's press release misrepresented the agreement and was inconsistent with it, noting the order does not address product safety. The company also said it supports additional oversight and regulation of clinical generative AI and signed the agreement to advance that conversation. A second and separate governance consideration now applies: since the September 2025 acquisition the documentation product is marketed as generating notes optimised for reimbursement from the start and identifying missed revenue opportunities, which places it on the coding gradient this index tracks, in the tight loop shape where documentation and revenue sit inside one platform with no vendor boundary between them. No fairness, subgroup or demographic performance disclosure of any kind was located.

The right architectural shape with the naming gap this index consistently calls out. The platform is described as operating directly within the electronic health record, condensing and summarising clinical data in place and pre generating progress notes, discharge summaries and multidisciplinary care plans, and it reaches three separate role types inside the same system. Deployment at multiple large hospital systems corroborates that this is real embedded delivery rather than copy and paste. Held at B because no EHR vendor is named on any retrieved surface and no integration mechanism, standard or certification is described, so an organisation cannot confirm its own system is supported without asking.

The platform is described as cloud hosted, which establishes a single hosted delivery model with no on premise option offered. Beyond that nothing is published: no cloud provider, no region, no residency commitment and no customer choice over where clinical data is processed. The acquisition adds a question that did not exist before, since the hosting arrangement and the corporate entity behind it both changed in September 2025 without any published statement about what moved where.

No pricing, tier, mechanism or contracting detail is published for the Pieces product or for SmarterNotes. Not Rated is the house convention for absent pricing rather than a low grade. Note that the commercial surface is now harder to assess than before the acquisition, because the summarisation capability is sold inside a broader revenue cycle platform and it is not stated whether it can be licensed separately.

Inpatient acute care, and distinctive for who it serves rather than for which specialties. This is the only product in this category so far that explicitly addresses CASE MANAGERS alongside physicians and nurses, generates MULTIDISCIPLINARY CARE PLANS as a first class output, and has tracked barriers to discharge as a named capability. Most of this category assumes a physician reading a chart before a visit; this one reaches the discharge planning and care coordination workflow, which is a different job with a different failure cost. Graded B rather than A because the breadth is by role and document type rather than by demonstrated specialty specific behaviour, and no specialty level depth was located.